Figures
Abstract
Diabetes-related infection has become a difficult and significant global public health issue. Estrogen has specific hormones that promote cutaneous wounds in diabetic mice. However, the impact of estrogen on skin-colonized pathogenic bacteria is unknown. The purpose of this study was to look into how estrogen affects wounds infected with Staphylococcus aureus. Nondiabetic db/ + mice and diabetic db/db mice were both injured, and bacterial suspension was applied to each wound site. Estrogen or vehicles were injected intraperitoneally every 3–4 days after wounding. S. aureus infection impaired diabetic wounds and reduced collagen deposition. Immunostaining revealed that S. aureus infection reduced the number of blood and lymphatic vessels while increasing the number of neutrophils in nondiabetic wounds, regardless of estrogen treatment. Conversely, estrogen administration reduced the number of macrophages in S. aureus-infected nondiabetic wounds compared to vehicle-treated wounds. The number of lymphatic vessels was roughly double that of estrogen administration in S. aureus-infected nondiabetic wounds. Our findings showed that S. aureus infection in diabetic wounds delayed cutaneous wound healing due to excessive inflammation, inhibited collagen deposition, and impaired angiogenesis or lymphangiogenesis, although estrogen administration did not reverse these effects. Our findings also revealed that estrogen administration effectively treated S. aureus-infected nondiabetic wounds by regulating the immune response and increasing the synthesis of lymphatic vessels.
Citation: Mukai K, Ogura K, Nakajima Y, Nakatani T (2025) The evaluation of the effect of estrogen administration on cutaneous wound healing in Staphylococcus aureus-infected diabetic and nondiabetic mice. PLoS One 20(12): e0339341. https://doi.org/10.1371/journal.pone.0339341
Editor: Nan Jiang, Southern Medical University Nanfang Hospital, CHINA
Received: July 4, 2025; Accepted: December 7, 2025; Published: December 30, 2025
Copyright: © 2025 Mukai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by JSPS KAKENHI (Grant Number JP23K21528). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Diabetes mellitus individuals with foot ulcers had a higher mortality rate [1,2] and high incidence of lower extremity amputation [3,4] than diabetes mellitus patients without ulceration. Diabetic ulcers are regarded as major issues in wound care. Diabetes disrupts cutaneous wound healing by causing prolonged and excessive inflammation [5] or insufficient angiogenesis [6]. Vascular changes and insufficient oxygen delivery also impair leukocyte migration into wounds, raising the risk of infections [7]. Bacterial infection is a major cause of impaired diabetic wound healing [8]. Furthermore, individuals with diabetes mellitus who have diabetic wounds have a 50% higher risk of amputation compared to those who do not have infections [9]. As a result, diabetes-related infections have emerged as a complex and significant global public health issue.
According to the microbiological profile of infected diabetic foot ulcers, the majority of the isolates are gram-positive bacteria (67.5%), with the frequently isolated species being Staphylococcus aureus (S. aureus), accounting for 16.8% [10]. Several other studies have also found that S. aureus was the most commonly isolated pathogen, with frequencies of 17.0% [10], 38.4% [11], 76% [12], and 58% [13]. Furthermore, a recent cohort study found that S. aureus was responsible for the persistent infection of diabetic ulcer osteomyelitis [14].
Estrogen is a hormone that promotes cutaneous wound healing in menopausal women [15] and older people [16]. Microarray analyses have revealed that estrogenic sex hormones play an important role in cutaneous wound healing [17]. A recent review also reported that estrogen plays a pivotal role in the clinical treatment of skin wounds due to its multifaceted effects on the wound healing process [18]. In animal studies, estrogen administration promotes cutaneous wound healing even in the presence of delayed systemic factors such as aging [19], malnutrition [20], and diabetes mellitus [21,22]. Previous research has shown that estrogen promotes cutaneous wound healing in Klebsiella. pneumoniae (K. pneumoniae) infected wounds [23]. K. pneumoniae is a gram-negative bacterium found in surgical wounds [24] and burns [25], but is uncommon in infected diabetic wounds. To date, the effect of estrogen on S. aureus, which is often isolated in diabetic ulceration [10–13] infected diabetic conditions, is unknown.
A global epidemiology analysis using a systematic review and meta-analysis revealed that the global prevalence of diabetic ulceration was higher in type 2 diabetics than in type-1 diabetics [26]. To conduct basic research on diabetic, genetically induced, or high-fat feeding rodents with hyperglycemia, which are commonly used as type-2 diabetes models. Among these type-2 diabetes models, genetically induced db/db mice show the following characteristics of human type-2 diabetes: obesity caused by hyperglycemia, insulin resistance, polydipsia, and polyuria [27]. Furthermore, db/db mice have demonstrated the pathogenesis of human type-2 diabetes complications, including susceptibility to infection and impaired wound healing [28,29]. As a result, in this study, we used db/db mice for the type-2 diabetes model as well as its heterozygous (db/+) mice, and we investigated the effect of estrogen in S. aureus-infected with wounds from db/db diabetic and db/ + nondiabetic mice.
Materials and methods
Animals
A total of twenty 10-week-old female db/ + mice (C57BLKS/J Iar- + m+ / + Leprdb) and twenty 10-week-old female db/db mice (C57BLKS/J Iar- + Leprdb/ + Leprdb) with diabetes from Sankyo Lab Service, Tokyo, Japan, were included in the experiments. Blood sugar levels were above 400 mg/dL in db/db mice and around 200 mg/dL in db/ + mice (S1 Fig). Individuals were placed in an air-conditioned room at 25.0°C ± 2.0°C with lights turned on from 08:45–20:45. Water and food were freely provided.
Staphylococcus aureus (S. aureus) culture collection
S. aureus strain N315 (ST5-SCCmec II lineage) was supplied by Dr. Keiichi Hiramatsu [30]. S. aureus was cultured overnight at 37°C in Todd-Hewitt broth (Becton and Dickinson, NJ, USA) with 0.5% yeast extract (Becton and Dickinson) (THY broth medium) overnight at 37°C as per a previous study [31]. Bacterial cells were centrifuged and washed with sterile phosphate-buffered saline (PBS) when the culture reached the exponential phase (OD600 = 0.5).
Wounding and S. aureus application
Mice were anesthetized with 1.5%–2.0% isoflurane (FUJIFILM Wako Pure Chemical, Tokyo, Japan) and 1.5 L of O2/min through a plastic tube mask. The dorsal fur was removed with clippers and depilatory cream on the day of the wounds, and the dorsum was cleaned with alcohol. Estradiol benzoate (estra-1,3,5(10)-triene-3,17β-diol 3-benzoate) (OVAHORMON®INJECTION; ASKA Pharmaceutical, Tokyo, Japan) at a dose of 1 mg/kg body weight or vehicle (sesame oil; FUJIFILM Wako Pure Chemical) was administered intraperitoneally (i.p.) every 3–4 days at the time of the wound dressing change. Two circular full-thickness skin wounds (with a 4-mm diameter) in the panniculus carnosus muscle were created on either side of the dorsum using a sterile disposable biopsy punch (Kai Industries, Gifu, Japan). Then, 10 μL of bacterial suspension (0.5 × 108 colony-forming units (CFU)/mL S. aureus) was spotted directly onto the surface of each wound following previous studies [28,29] and our preliminary data (S2 Fig). The wounds were covered with film dressing (Tegaderm; 3M Health Care, Tokyo, Japan) and changed every 3–4 days. Mice were kept in cages and their health was observed after induction of the infection every 1–2 days. The body weights were recorded at the time before changing the wound dressing or health observation (S3 Fig). The mice were divided into four groups and each group comprised of 10 animals (n = 10): S. aureus-infected nondiabetic vehicle administration (SA db/+), S. aureus-infected nondiabetic estrogen administration (SA db/ + estrogen), S. aureus-infected diabetic vehicle administration (SA db/db), and S. aureus-infected diabetic estrogen administration (SA db/db estrogen). On days 7 and 14 after wounding (post-infection), five mice from each group were sacrificed with isoflurane overdose and effectiveness of the treatment was evaluated using a variety of parameters. No mice reached the humane endpoint (weights loss over 20% of the initial body weight).
Bacterial colony counting
The wound dressings were removed from the mice and suspended in tubes containing 30-mL PBS on days 3, 7, and 14. Then, each bacterial solution was vigorously mixed, serially diluted tenfold, and plated on THY agar plates. After incubation at 37°C for 24h, CFU were counted.
Macroscopic observations
Day 0 was defined as the day wounds were created, and the process of wound healing was monitored until day 14. The wound area was measured using photographs taken on days 0, 3, 7, 10, 12, and 14. We calculated the wound areas with ImageJ (National Institutes of Health, MD, USA) and presented them as the ratio of daily wound area-to-initial wound area on day 0, as in previous studies [22,32].
Tissue collection
The mice were sacrificed with isoflurane overdose on days 7 and 14. The wound and surrounding intact skin were harvested, and each wound and surrounding intact skin sample was cut in the center. Half of each wound was treated with 4% paraformaldehyde (PFA) (FUJIFILM Wako Pure Chemical) and embedded in tissue-Tek OCT (Sakura Finetek, Tokyo, Japan).
Staining
At least six serial ice sections were taken from a wound and stained near its center. Subsequently, 5–10-μm-thick ice sections were subjected to hematoxylin and eosin (HE) staining and collagen staining (K-61, Collagen Research Center, Tokyo, Japan), and immunohistologically stained with anti-neutrophil antibody at a dilution of 1:1000 (ab2557; Abcam, Cambridge, UK) to detect neutrophils, anti-Mac-3 antibody at a dilution of 1:1000 (550292; BD Pharmingen, Tokyo, Japan) to identify macrophages, and anti-cluster of differentiation 31 (CD31) antibody at a dilution of 1:50 (550274; BD Pharmingen) to detect blood vessels, and anti-lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) antibody at a dilution of 1:1000 (103-PA50; RELIA Tech GmbH, Wolfenbüttel, Germany) to identify lymphatic vessels per the manufacturer’s instructions with a slight modification. Negative control slides were created by removing each primary antibody.
Microscopic observations
Staining images were transferred to a computer via a digital microscopic camera (DP27-CU; Olympus, Tokyo, Japan). The re-epithelialization ratio (re-epithelialization length/wound length) was calculated using DP27-CU according to previous studies [19,22]. The ratio of collagen deposition (collagen pixels/total wound pixels) was determined using Adobe Photoshop Elements 25.7 (Adobe System, Tokyo, Japan) following previous research [20]. The number of positive inflammatory cells was counted with ImageJ at three wound sites, × 400 magnification, and divided by the area. The number of positive vessels was counted using ImageJ software at three wound sites, × 200 magnification, and divided by the area.
Ethical statement
Animal experiments in this study were reviewed and approved by the Kanazawa University Animal experiment committee, and they were carried out following the guidelines for the care and use of laboratory animals of Kanazawa University (AP-224323). Bacterial experiments were carried out following the WHO Laboratory biosafety manual and the microorganism safety management regulations of Kanazawa University.
Statistical analysis
Data were presented as means ± standard error of the mean (SEM) and analyzed using JMP® 12.1.0 (SAS, NC, USA). The means of multiple groups were compared using one-way analysis of variance (ANOVA), followed by post hoc pairwise comparisons with the Tukey–Kramer multiple comparison test. A p-value of <0.05 indicated statistical significance.
Results
S. aureus bacterial burden
The S. aureus counts were not elevate on day 3 postinfection compared to the initial application (106 CFU) in all four groups. Subsequently, the S. aureus bacterial burden differed between nondiabetic and diabetic mice. In the non-diabetes group, the S. aureus counts elevated on day 7 (1.0 × 108 ± 4.0 × 107 CFU in the SA db/ + group and 1.0 × 108 ± 3.0 × 107 CFU in the SA db/ + estrogen group) and then decreased on day 14 (2.0 × 106 ± 2.0 × 106 CFU in the SA db/ + group and 3.0 × 104 ± 2.0 × 104 CFU in the SA db/ + estrogen group). However, in the diabetes group, S. aureus counts were elevated on days 7 (1.0 × 108 ± 4.0 × 107 CFU in the SA db/db group and 2.0 × 108 ± 1.0 × 108 CFU in the SA db/db estrogen group) and 14 (2.0 × 108 ± 1.0 × 108 CFU in the SA db/db group and 3.0 × 108 ± 1.0 × 108 CFU in the SA db/db estrogen group). The SA db/db estrogen group had significantly larger S. aureus counts compared to the SA db/+ and SA db/ + estrogen groups on day 14 (p < 0.05) (Fig 1).
Body weight
The initial body weights (before wounding) were 22.1 ± 0.31 g in the SA db/ + group, 22.0 ± 0.44 g in the SA db/ + estrogen group, 38.6 ± 0.81 g in the SA db/db group, and 37.3 ± 0.41 g in the SA db/db estrogen group, respectively (S3 Fig). After days of wounding, the mean body weights in both vehicle treatment groups decreased by −3.4% in the SA db/ + group and −8.4% in the SA db/db group until day 14. In contrast, the mean body weights of both estrogen treatment groups increased by 4.8% in the SA db/ + estrogen group and 2.2% in the SA db/db estrogen group until 14.
Uterine changes with estrogen administration
The uterus became edematous and enlarged after estrogen administration. On day 14, nutrient vessels were thicker and had more blood in both the SA db/ + estrogen and SA db/db estrogen groups. Conversely, the uterus did not enlarge in the SA db/ + group and atrophied in the SA db/db group on day 14 (S4 Fig).
Macroscopic observations and the wound area
In nondiabetic group, the necrotic tissues appeared on day 3 and thickly covered the wound surface on day 7. Then, they were gradually removed from the wound surface until day 14 (Fig 2A). The wound areas progressively decreased until day 14 (day 7: 0.44 ± 0.05 in the SA db/ + group and 0.28 ± 0.03 in the SA db/ + estrogen group; day 14: 0.08 ± 0.03 in the SA db/ + group and 0.06 ± 0.01 in the SA db/ + estrogen group). In contrast, in diabetic group, necrotic tissues appeared on day 3 and thickened and covered the wound surface until day 14. Furthermore, the peri-wounds displayed redness and maceration (Fig 2A). The wound regions gradually decreased until day 14 (day 7: 0.64 ± 0.09 in the SA db/db group and 0.81 ± 0.12 in the SA db/db estrogen group, day 14: 0.31 ± 0.12 in the SA db/db group and 0.37 ± 0.08 in the SA db/db estrogen group). The ratio of wound area in the SA db/db group was significantly larger on days 3 and 10 (p < 0.05) and tended to be larger on day 12 (p = 0.080) compared to the SA db/ + group, and significantly larger on days 3–12 (p < 0.05) and tended to be larger on day 14 (p = 0.071) comapred to the SA db/ + estrogen group. Moreover, the ratio of wound area in the SA db/db estrogen group was significantly larger than that of the SA db/ + group on days 3–14 (p < 0.05), as well as the SA db/ + estrogen group on days 3–14 (p < 0.05) (Fig 2B).
(A) Wounds of 4 mm diameter are created, and images are taken to assess wound healing. Scale bar, 5 mm. (B) The wound area-to-initial area ratios on day 0 are depicted as line graphs for each day. Values are presented as means ± SEM, n = 10 wounds; ANOVA, Tukey’s HSD test, **p < 0.01, *p < 0.05 and †p < 0.1: versus the SA db/ + group and ¶¶p < 0.01,¶p < 0.05 and †p < 0.1: versus the SA db/ + estrogen group. SA: S. aureus.
Re-epithelialization and collagen deposition
In the nondiabetes group, the new epithelium extended from the wound edges on day 7 and covered the wound surface on day 14, with collagen synthesis progressively increasing from day 7 to day 14. Conversely, in diabetic group, the new epithelium did not spread from the wound edges on day 7 and did not cover the wound surface on day 14, and collagen synthesis progressed slowly until day 14. The ratio of re-epithelialization in the SA db/db group tended to be lower than that of the SA db/ + group on day 7 (p = 0.058), and in the SA db/db estrogen group tended to be lower than that of the SA db/ + estrogen group on day 14 (p = 0.082) (Fig 3A and 3B). The ratio of collagen deposition in the SA db/db group was significantly lower on day 7 (p < 0.05) and tended to be lower on day 14 (p = 0.098) compared to the SA db/ + group and significantly lower than that in the SA db/ + estrogen group on days 7 and 14 (p < 0.05). The ratio of collagen deposition in the SA db/db estrogen group was significantly lower than that in the SA db/+ and SA db/ + estrogen groups on day 14 (p < 0.05) and tended to be lower than that in the SA db/ + estrogen group on day 7 (p = 0.070) (Fig 3C and 3D).
(A) The ratio of re-epithelialization (%) on days 7 and 14 is illustrated as a box graph. Values are presented as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, †p < 0.1: compared to SA db/+ or SA db/ + estrogen groups. (B) hematoxylin and eosin staining (bars, 200 µm) on days 7 and 14. Arrows represent wound edges. (C) The ratio of collagen pixel/wound pixel (%) on days 7 and 14 is illustrated in a box graph. Values are presented as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, *p < 0.05 and †p < 0.1: versus the SA db/ + group and ¶¶p < 0.01, ¶p < 0.05 and †p < 0.1: versus the SA db/ + estrogen group. (D) Collagen staining (bars, 200 µm) on days 7 and 14. Arrows signify the wound edges. SA: S. aureus.
Inflammatory cells
The nondiabetes group had many inflammatory cells, such as neutrophils and macrophages, at the wounds on day 7. Subsequently, neutrophils and macrophages considerably decreased in the SA db/ + estrogen group on day 14. In contrast to the SA db/ + group, neutrophils considerably decreased on day 14, whereas macrophages remained at the wounds on day 14. In contrast, in diabetic group, many neutrophils and macrophages were present at the wounds on day 7 and remained on day 14. The neutrophil counts in the SA db/db group was significantly higher on days 7 and 14 compared to the SA db/+ and SA db/ + estrogen groups (p < 0.05). The neutrophil counts in the SA db/db estrogen group was significantly higher than that in the SA db/ + group on day 14 (p < 0.05) and tended to be higher than that in the SA db/ + estrogen group on day 14 (p = 0.060) (Fig 4A and 4B). The macrophages counts in the SA db/db group was significantly higher than that of the SA db/ + estrogen group on days 7 and 14 (p < 0.05). The macrophages counts in the SA db/db estrogen group was significantly higher than that of the SA db/ + estrogen group on day 14 (p < 0.01). Moreover, the macrophages counts in the SA db/ + group was significantly larger than that of the SA db/ + estrogen group on day 14 (p < 0.05) (Fig 4C and 4D). Additionally, the relative expression of the Tnf-α in the SA db/db group was greatly higher than that in the SA db/+ and SA db/ + estrogen groups on day 14 (p < 0.01) (S5 Fig).
(A) The number of neutrophils/mm2 on days 7 and 14 is illustrated in a box graph. Values are given as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, *p < 0.05: versus the SA db/ + group and ¶¶p < 0.01, ¶p < 0.05 and †p < 0.1: versus the SA db/ + estrogen group. (B) Anti-neutrophil antibody immunohistochemistry staining (bars, 20 µm) on days 7 and 14. (C) The number of macrophages/mm2 on days 7 and 14 is shown in a box graph. Values are presented as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, ¶¶p < 0.01 and ¶p < 0.05: compared to the SA db/ + estrogen group. (D) Anti-macrophage antibody immunohistochemistry staining (bars, 20 µm) on days 7 and 14. S. aureus.
New blood and lymphatic vessels
In the nondiabetes group, many CD31 positive blood vessels appeared at the wounds on day 7, and they were retained on day 14. LYVE-1 positive lymphatic vessels were uncommon on day 7, but there were numerous observed on day 14. In particular, the number of LYVE-1-positive lymphatic vessels in the SA db/ + estrogen group was roughly double that of the SA db/ + group. Conversely, in diabetic group, CD31 positive blood vessels were rarely seen on day 7, and they gradually increased on day 14. There were no LYVE-1 positive lymphatic vessels observed at the wounds on day 7 and only a few on day 14. The CD31 positive blood vessels in the SA db/db and SA db/db estrogen groups were significantly lower on day 7 compared to the SA db/+ and SA db/ + estrogen groups (p < 0.05) (Fig 5A and 5B). The LYVE-1 positive lymphatic vessels in the SA db/db group was significantly lower than that of the SA db/ + estrogen group on days 7 and 14 (p < 0.05). The LYVE-1 positive lymphatic vessels in the SA db/db estrogen group tended to be lower on day 7 (p = 0.099) and significantly lower on day 14 (p < 0.01) compared to the SA db/ + estrogen group (Fig 5C and 5D).
(A) A box graph illustrates the number of CD31 positive blood vessels/mm2 on days 7 and 14. Values are given as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, **p < 0.01, *p < 0.05: versus the SA db/ + group and ¶¶p < 0.01: versus the SA db/ + estrogen group. (B) Anti-CD31 antibody immunohistochemistry staining (bars, 40 µm) on days 7 and 14. (C) The number of LYVE-1 positive lymphatic vessels/mm2 on days 7 and 14 is represented in a box graph. Values are presented as means ± SEM, n = 5–9 wounds; ANOVA, Tukey’s HSD test, ¶¶p < 0.01, ¶p < 0.05, and †p < 0.1: compared to the SA db/ + estrogen group. (D) Anti-LYVE-1 antibody immunohistochemistry staining (bars, 40 µm) on days 7 and 14. Arrows indicate lymphatic vessels. S. aureus.
Discussion
Diabetic wounds pose a persistent clinical challenge due to delayed cutaneous wound healing and a higher likelihood of infection and complications. Estrogen contains specific hormones that promote cutaneous wounds in diabetic mice [21,22], and those infected with K. pneumonia [23]. However, the effect of estrogen on S. aureus, which is often isolated from species in diabetic infected ulceration [10–13], is unclear. Therefore, this study sought to investigate the effect of estrogen on the wounds of S. aureus. As a result, our study found that S. aureus infection in diabetic wounds slowed wound healing and was not reversed by estrogen administration. The current findings also revealed that estrogen administration reduced the inflammatory response by lowering the number of macrophages and may promote the formation of new lymphatic vessels in S. aureus-infected nondiabetic wound healing.
S aureus-infected wound models were tested using 10 μL of bacterial suspension (1.0 × 107 CFU/mL) in C57BL/6J and db/db mice [28], 20 μL of bacterial suspension (1.0 × 108 CFU/mL) in Balb/c [33], and 10 μL of bacterial suspension (108 CFU/mL) in db/+ and db/db mice [29]. Following these previous studies’ settings, we have set to apply 10 μL of bacteria suspension (0.5 × 108 CFU/mL S. aureus) to each wound in db/+ and db/db mice, successfully increasing the number of S. aureus on the wound dressing. These findings indicate that the number of bacteria administered in the current setting was sufficient to cause infected wounds. Furthermore, the current study confirmed uterine morphology changes after estrogen administration. The uterus of estrogen-treated mice was edematous and enlarged, with thick, blood-rich nutrient vessels (S4 Fig). Previous studies found that estrogen administration significantly increased uterine size [34] and weight [22]. As a result, the current study concluded that estrogen replacement was sufficient.
Diabetic wounds have an impact on all stages of cutaneous wound healing by increasing inflammatory cell infiltration [35], impairing angiogenesis [36], and degrading extracellular matrix [37]. Wound healing in diabetic mice is slowed by S. aureus bacterial species infection [29,38,39]. Similar to previous studies, S. aureus infection in diabetic mice did not result in a smaller wound area, and re-epithelialization was incomplete. The current study also found that S. aureus infected in diabetic mice had longer inflammation responses and impaired collagen depositions, angiogenesis, and lymphangiogenesis compared to nondiabetic mice. Furthermore, the body weights loss remained within 20% in diabetic and nondiabetic mice. Previous studies had created larger or more wounds than the current study, such as two 8 mm full-thickness [38], 6 mm full-thickness [39], or 3 mm full-thickness at six sites [29]. Weight loss within 14 days was 40% [38], with 14-day overall survival of S. aureus-infected diabetic mice at 73% and non-infected diabetic mice at 98% [39]. As a result, it is believed that the adverse events were minor in comparison to previous studies and that S. aureus infection in diabetic wounds was delayed.
Unfortunately, estrogen administration did not improve diabetic cutaneous wound healing with S. aureus infection. Several previous studies have found that estrogen plays an important immunomodulatory role in microbial infections, directly or indirectly influencing bacterial growth, survival, and virulence [40–42]. However, the number of S. aureus was not lowered by estrogen i.p. administration during wound healing in diabetes. It is possible that the promoting effect of estrogen i.p. administration was strongly influenced by S. aureus infection in diabetic mice, resulting in delayed wound healing. Meanwhile, the current study found that estrogen administration reduced the macrophages in nondiabetic S. aureus-infected wounds, but the healing time was not reduced. Previous research demonstrated that estrogen regulates the innate immune response to S. aureus [43,44]. Furthermore, an in vitro study found that estrogen acts as an immune protectant in the monocyte/macrophage response induced by S. aureus [45]. As a result, these findings demonstrated that estrogen is effective in regulating immune response to S. aureus in nondiabetic wounds.
Lymphangiogenesis and lymphatic vessel remodeling are intricate biological processes [46], and S. aureus causes lymphatic dysfunction [47]. In the current study, lymphatic vessels were approximately twice as numerous in nondiabetic S. aureus-infected wounds with estrogen administration compared to vehicle administration. Furthermore, they were significantly more numerous than diabetic S. aureus-infected wounds. A previous study found that estrogen increases the transcriptional activation of lymphangiogenesis-related gene expression [47]. These findings suggest that estrogen administration may act to promote lymphangiogenesis in nondiabetic wounds against S. aureus infection. Impaired lymphangiogenesis in diabetic ulcers causes clinical delays [48], and lymphangiogenesis is being studied as a potential therapeutic target for nonhealing wounds [46]. Therefore, more research is needed to elucidate the lymphangiogenesis mechanism and its relationship with estrogen in nonhealing wound models.
The current study experiments used only one bacterium, S. aureus straion N315. The virulence of S. aureus varies depending on its virulence factors. For example, Panton–Valentine leukocidin (PVL), a virulence factor produced by some S. aureus isolates, is associated with severe skin infection outcomes [49]. Strain N315 belongs to ST5–SCCmec II and possess no pvl (lukS-PV or lukF-PV) gene. Whether similar results could be obtained using other bacterial strains or more virulent S. aureus species remains unclear. Further studies are needed to establish alternative bacterium-infected wound models. Moreover, the current study employed only i.p. administration. Whether similar results could be obtained with topical estrogen application or a combination with i.p. and topical remains unclear. Further research is required to evaluate the effectiveness of estrogen through other administration routes in bacterium-infected diabetic wounds.
Conclusion
Our findings showed that S. aureus-infected wounds in diabetic mice delayed wound healing by causing excessive inflammation, inhibiting collagen deposition, angiogenesis, and lymphangiogenesis, although these changes did not improve with estrogen administration. Furthermore, the current study found that estrogen administration was effective in treating S. aureus-infected wounds in nondiabetic mice by regulating the immune response and increasing the synthesis of lymphatic vessels. As a result, such treatment may partially improve healing in nondiabetic S. aureus-infected wounds.
Supporting information
S1 Fig. Blood sugar (mg/dL) before and after fasting (2h, 4h and 6h).
Values are expressed as means ± SEM, n = 6 mice per group.
https://doi.org/10.1371/journal.pone.0339341.s001
(PDF)
S2 Fig. Colony-forming units of S. aureus in WT mice.
The colony forming units (CFU) of S. aureus at the wound dressing are shown as a box graph on days 1 (24h), 2 (42h) and 3 (72h). SA: S. aureus.
https://doi.org/10.1371/journal.pone.0339341.s002
(PDF)
S3 Fig. Body weights.
The body weights on each day are depicted as a line graph. Values are expressed as means ± SEM. SA: S. aureus.
https://doi.org/10.1371/journal.pone.0339341.s003
(PDF)
S4 Fig. Uterus.
The photographs of uterus are shown on day 14. Arrows indicate the atrophied uterus. Bar, 5 mm. SA: S. aureus.
https://doi.org/10.1371/journal.pone.0339341.s004
(PDF)
S5 Fig. Relative expression of inflammatory cytokines.
Values are expressed as means ± SEM, n = 7–9 wounds; ANOVA, Tukey’s HSD test, **p < 0.01: versus the SA db/ + group and ¶¶p < 0.01: versus the SA db/ + estrogen group. The primer sequences (Tnf-α, Il-6, and Gapdh) were used according to previous research (https://doi.org/10.1007/s00403-025-03883-y). SA: S. aureus.
https://doi.org/10.1371/journal.pone.0339341.s005
(PDF)
Acknowledgments
The authors would like to thank Enago (www.enago.jp) for the English language review.
References
- 1. Walsh JW, Hoffstad OJ, Sullivan MO, Margolis DJ. Association of diabetic foot ulcer and death in a population-based cohort from the United Kingdom. Diabet Med. 2016;33(11):1493–8. pmid:26666583
- 2. Saluja S, Anderson SG, Hambleton I, Shoo H, Livingston M, Jude EB, et al. Foot ulceration and its association with mortality in diabetes mellitus: a meta-analysis. Diabet Med. 2020;37(2):211–8. pmid:31613404
- 3. Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. Diabetes Care. 2008;31(7):1331–6. pmid:18390800
- 4. Gong H, Ren Y, Li Z, Zha P, Bista R, Li Y, et al. Clinical characteristics and risk factors of lower extremity amputation in the diabetic inpatients with foot ulcers. Front Endocrinol. 2023;14.
- 5. Zhao R, Liang H, Clarke E, Jackson C, Xue M. Inflammation in Chronic Wounds. Int J Mol Sci. 2016;17(12):2085. pmid:27973441
- 6. Dasari N, Jiang A, Skochdopole A, Chung J, Reece EM, Vorstenbosch J, et al. Updates in Diabetic Wound Healing, Inflammation, and Scarring. Semin Plast Surg. 2021;35(03):153–8.
- 7. Greenhalgh DG. Wound healing and diabetes mellitus. Clinics in Plastic Surgery. 2003;30(1):37–45.
- 8. Lavery LA, Suludere MA, Ryan E, Crisologo PA, Tarricone A, Malone M, et al. The infected diabetic foot: Analysis of diabetic and non-diabetic foot infections. Wound Repair Regen. 2024;32(4):360–5. pmid:38426336
- 9. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29(6):1288–93. pmid:16732010
- 10. Ge Y, MacDonald D, Hait H, Lipsky B, Zasloff M, Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabetic Medicine. 2002;19(12):1032–4.
- 11. Copari-Vargas E, Copari-Vargas LE, Copari-Vargas TL, Domínguez-Valdez LF, Copari-Jimenez E, Urquizo-Ayala JG. Bacteriological Profile and Antibiotic Susceptibility in Patients With Diabetic Foot Infections. Cureus. 2025.
- 12. Kulasegaran N, Vangaveti V, Norton R, Malabu U. The Microbial Diversity and Antimicrobial Susceptibility Profile Underlying Diabetic Foot Osteomyelitis: A Retrospective Study Conducted in North Queensland, Australia. Foot Ankle Orthop. 2024;9(3):24730114241281503. pmid:39380709
- 13. Choi Y, Oda E, Waldman O, Sajda T, Beck C, Oh I. Next-Generation Sequencing for Pathogen Identification in Infected Foot Ulcers. Foot Ankle Orthop. 2021;6(3):24730114211026933. pmid:35097461
- 14. Metaoy S, Rusu I, Pillai A. Microbial profile of diabetic foot osteomyelitis from the northwest of England. Clin Diabetes Endocrinol. 2024;6:1–11.
- 15. Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med. 1997;3(11):1209–15. pmid:9359694
- 16. Ashcroft GS, Greenwell-Wild T, Horan MA, Wahl SM, Ferguson MW. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol. 1999;155(4):1137–46. pmid:10514397
- 17. Hardman MJ, Ashcroft GS. Estrogen, not intrinsic aging, is the major regulator of delayed human wound healing in the elderly. Genome Biol. 2008;9(5).
- 18. Li Z, Ma R, Tan J, Li C, Xiao Y, Qiu X, et al. Hormonal interventions in skin wounds – a mini review. Mol Med. 2024;30(1).
- 19. Mukai K, Nakajima Y, Asano K, Nakatani T. Topical estrogen application to wounds promotes delayed cutaneous wound healing in 80-week-old female mice. PLoS One. 2019;14(11):e0225880. pmid:31774863
- 20. Mukai K, Komatsu E, Nakajima Y, Urai T, Nasruddin, Sugama J, et al. The effect of 17β-estradiol on cutaneous wound healing in protein-malnourished ovariectomized female mouse model. PLoS One. 2014;9(12):e115564. pmid:25518000
- 21. Zhuge Y, Regueiro MM, Tian R, Li Y, Xia X, Vazquez-Padron R, et al. The effect of estrogen on diabetic wound healing is mediated through increasing the function of various bone marrow-derived progenitor cells. Journal of Vascular Surgery. 2018;68(6):127S-135S.
- 22. Mukai K, Horike S-I, Meguro-Horike M, Nakajima Y, Iswara A, Nakatani T. Topical estrogen application promotes cutaneous wound healing in db/db female mice with type 2 diabetes. PLoS One. 2022;17(3):e0264572. pmid:35271602
- 23. Crompton R, Williams H, Ansell D, Campbell L, Holden K, Cruickshank S, et al. Oestrogen promotes healing in a bacterial LPS model of delayed cutaneous wound repair. Lab Invest. 2016;96(4):439–49. pmid:26855364
- 24. Qiao L, Gao H, You Y, Zhu J. Analysis of the distribution characteristics of infecting microorganisms in the wound tissue of patients with perianal abscess combined with infection and the influencing factors of wound healing. BMC Gastroenterol. 2025;25(1):258. pmid:40234777
- 25. El Hamzaoui N, Barguigua A, Larouz S, Maouloua M. Epidemiology of burn wound bacterial infections at a Meknes hospital, Morocco. New Microbes New Infect. 2020;38:100764. pmid:33163199
- 26. Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis †. Ann Med. 2017;49(2):106–16. pmid:27585063
- 27. Singh R, Gholipourmalekabadi M, Shafikhani SH. Animal models for type 1 and type 2 diabetes: advantages and limitations. Front Endocrinol (Lausanne). 2024;15:1359685. pmid:38444587
- 28. Dolivo D, Lanier S, Leung K, Mustoe T, Hong SJ, Galiano R. Comparative transcriptomic adaptations of Staphylococcus aureus to the wound environment in non‐diabetic and diabetic mice. Wound Repair Regeneration. 2022;30(5):541–5.
- 29. Kishibe M, Griffin TM, Goslawski M, Sinacore J, Kristian SA, Radek KA. Topical nicotinic receptor activation improves wound bacterial infection outcomes and TLR2-mediated inflammation in diabetic mouse wounds. Wound Repair Regen. 2018;26(6):403–12. pmid:30264418
- 30. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001;357(9264):1225–40. pmid:11418146
- 31. Furuya H, Ogura K, Takemoto N, Watanabe S, Yamazaki A, Ogai K, et al. A multilocus sequence typing method of Staphylococcus aureus DNAs in a sample from human skin. Microbiol Immunol. 2023;67(10):438–46. pmid:37574717
- 32. Mukai K, Nakatani T. Comparison of different modern wound dressings on full-thickness murine cutaneous wound healing with wild-type and type-2 diabetes db/db mice. J Tissue Viability. 2024;33(4):616–24. pmid:39349341
- 33. Wang G, Huang Y, Shi Y, Han Q, Zhang J, Song Y, et al. The novel cathelicidin-DM antimicrobial peptide conjugated carbomer and thermosensitive chitosan hydrogel speeds up wound-healing in both non-infected and S. aureus-infected wounds. International Journal of Biological Macromolecules. 2025;288:138659.
- 34. Cheng Y, Lv Q, Xie B, Yang B, Shan W, Ning C, et al. Estrogen and high-fat diet induced alterations in C57BL/6 mice endometrial transcriptome profile. Endocr Connect. 2018;7(1):36–46. pmid:29133384
- 35. Brem H, Tomic-canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117:1219–22.
- 36. Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Mol Life Sci. 2016;73(20):3861–85. pmid:27180275
- 37. Xue M, Jackson CJ. Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring. Adv Wound Care (New Rochelle). 2015;4(3):119–36. pmid:25785236
- 38. Wei S, Xu P, Yao Z, Cui X, Lei X, Li L, et al. A composite hydrogel with co-delivery of antimicrobial peptides and platelet-rich plasma to enhance healing of infected wounds in diabetes. Acta Biomater. 2021;124:205–18. pmid:33524559
- 39. Huon J-F, Gaborit B, Caillon J, Boutoille D, Navas D. A murine model of Staphylococcus aureus infected chronic diabetic wound: A new tool to develop alternative therapeutics. Wound Repair Regen. 2020;28(3):400–8. pmid:32134548
- 40. Vázquez-Martínez ER, García-Gómez E, Camacho-Arroyo I, González-Pedrajo B. Sexual dimorphism in bacterial infections. Biol Sex Differ. 2018;9(1):27. pmid:29925409
- 41. Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics. Front Immunol. 2021;11:604000. pmid:33584674
- 42. Hong L, Liang H, Man W, Zhao Y, Guo P. Estrogen and bacterial infection. Front Immunol. 2025;16:1556683. pmid:40364840
- 43. Fahey JV, Rossoll RM, Wira CR. Sex hormone regulation of anti-bacterial activity in rat uterine secretions and apical release of anti-bacterial factor(s) by uterine epithelial cells in culture. J Steroid Biochem Mol Biol. 2005;93(1):59–66. pmid:15748833
- 44. Castleman MJ, Pokhrel S, Triplett KD, Kusewitt DF, Elmore BO, Joyner JA, et al. Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by α-Hemolysin. J Immunol. 2018;200(2):657–68. pmid:29222165
- 45. Souza CLSE, Barbosa CD, Coelho HILN, Santos Júnior MN, Barbosa EN, Queiroz ÉC, et al. Effects of 17β-Estradiol on Monocyte/Macrophage Response to Staphylococcus aureus: An In Vitro Study. Front Cell Infect Microbiol. 2021;11:701391. pmid:34336722
- 46. Renò F, Sabbatini M. Breaking a Vicious Circle: Lymphangiogenesis as a New Therapeutic Target in Wound Healing. Biomedicines. 2023;11(3):656. pmid:36979635
- 47. Jones D, Meijer EFJ, Blatter C, Liao S, Pereira ER, Bouta EM. Supplementary materials for lymphatic vessel dysfunction. Sci Transl Med. 2018.
- 48. Labanaris AP, Polykandriotis E, Horch RE. The effect of vacuum-assisted closure on lymph vessels in chronic wounds. J Plast Reconstr Aesthet Surg. 2009;62(8):1068–75. pmid:18524708
- 49. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2007;87(1):3–9. pmid:17146447